For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

Medicare doesn’t currently cover ketamine infusions for mental health conditions, as the Food and Drug Administration (FDA) only approves ketamine as a general anesthetic. However, it may cover ...

PharmaTher expects to submit the MINOR AMENDMENT to the CRL by end-February 2025 and expects a new approval date for a Q2-2025 FDA approval of ketamineTORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ...

Around that time, a doctor friend told him about ketamine for treatment-resistant depression. It wasn’t an FDA- approved treatment. But Winograd says it saved his life. But for every success s ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Ketamine also has come under increasing scrutiny as a treatment recently, with studies suggesting that for some patients it ...

PharmaTher (PHRRF) announced that the Company is on track to resubmit information to the FDA by end-February 2025. This resubmission, which ...

The FDA did not express concern about the stability of the ketamine submission batches, which achieved 18 months of stability without issue, and no new preclinical and clinical studies were requested.